SC 13D/A - SINOVAC BIOTECH LTD (0001084201) (Subject)

SC 13D/A - SINOVAC BIOTECH LTD (0001084201) (Subject)

SC 13G/A - SINOVAC BIOTECH LTD (0001084201) (Subject)

SC 13D/A - SINOVAC BIOTECH LTD (0001084201) (Subject)

SC 13D/A - SINOVAC BIOTECH LTD (0001084201) (Subject)

SC 13D/A - SINOVAC BIOTECH LTD (0001084201) (Subject)

SC 13D/A - SINOVAC BIOTECH LTD (0001084201) (Subject)

SC 13D/A - SINOVAC BIOTECH LTD (0001084201) (Subject)

Sinovac Biotech Ltd. ("Sinovac" or the "Company") (NASDAQ:SVA), a leading provider of biopharmaceutical products in China, today announced that its board of directors has amended its shareholder rights plan. The amendment extends the expiration date of the plan from February 22, 2024 to February 22, 2025. About SINOVAC Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of biomedical products that protect against human infectious diseases. SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected hand-foot-mouth disease (HFMD), hepatitis A, varicella, influenza, pol

Board of Directors Unanimously Recommends Sinovac Shareholders NOT Tender Shares for purchase pursuant to the Offer to Purchase Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, announced today that its Board of Directors (the "Board of Directors") unanimously determined that the partial tender offer (the "Tender Offer") by Alternative Liquidity Index LP ("Alternative Liquidity") to acquire up to 10,000,000 common shares of Sinovac (the "Shares") for $0.03 per share in cash (the "Offer Price") is NOT advisable and is NOT in the best interests of the Company or its shareholders ("Shareholders"). Accordingly, the Board

Clinical trials will advance treatment of COVID-19 infection. Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ:SVA), a leading provider of biopharmaceutical products in China, announced that the Company has completed the phase I clinical trial for its broad-spectrum neutralizing antibody product, the Anti-COVID-19 Antibody SA55 Injection ("SA55 Injection") in Beijing and has entered the phase II clinical trial in Shanghai after successfully enrolling its first participant recently. SINOVAC's SA55 Injection, which is intended for the treatment of COVID-19 infections, was approved for clinical trial in China on May 24, 2023. The phase I clinical trial has confirmed its preliminar

Board of Directors Unanimously Recommends Sinovac Shareholders NOT Tender Shares for purchase pursuant to the Offer to Purchase Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, announced today that its Board of Directors (the "Board of Directors") unanimously determined that the partial tender offer (the "Tender Offer") by Alternative Liquidity Index LP ("Alternative Liquidity") to acquire up to 10,000,000 common shares of Sinovac (the "Shares") for $0.03 per share in cash (the "Offer Price") is NOT advisable and is NOT in the best interests of the Company or its shareholders ("Shareholders"). Accordingly, the Board

Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, confirmed today that it is aware of an unsolicited partial tender offer from Alternative Liquidity Index LP to purchase up to a maximum of 10,000,000 shares of the Company, representing approximately 10.05% of the Company's outstanding shares, for $0.03 per share in cash. Sinovac's Board of Directors intends to evaluate the terms of the tender offer to determine the course of action that it believes is in the best interest of the Company and its shareholders. The Board also intends to advise shareholders of the Board's position regarding the tender offer within ten bu

Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, announced today that the Company's subsidiary, Sinovac Biotech Co., Ltd. ("Sinovac Beijing"), has changed its legal representative to Mr. Weidong Yin, the Company's Chairman, President and Chief Executive Officer. The Administration for Market Regulation Bureau of Beijing Haidian District notified Sinovac Beijing that the minority shareholder and the legal representative of Sinovac Beijing have been changed in accordance with the Notice of Assistance of Court Verdict Execution, the Verdict Execution Order and the Consent Judgement on the Civil Mediation Agreement by S

Sinovac Biotech Ltd. ("Sinovac" or the "Company") (NASDAQ:SVA), a leading provider of biopharmaceutical products in China, today announced that its board of directors has amended its shareholder rights plan. The amendment extends the expiration date of the plan from February 22, 2023 to February 22, 2024. About SINOVAC Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases. SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected hand-foot-mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pn

Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ:SVA), a leading provider of biopharmaceutical products in China, today announced that it received prequalification from the World Health Organization (WHO) for its live attenuated varicella vaccine on November 3, 2022. This marks the first WHO prequalified Chinese varicella vaccine and the fourth SINOVAC vaccine to receive WHO approval. The varicella vaccine is derived from the Oka strain and propagated in SINOVAC's proprietary Human Diploid Cell (SV-1 strain), which is made by culturing and harvesting the virus, adding stabilizers and freeze-drying. According to a phase III efficacy study, the seroconversion rate of the vaccinated

Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ:SVA), a leading provider of biopharmaceutical products in China, announced that the Company will participate in CPHI Frankfurt, one of the world's largest pharmaceutical exhibitions, from 1st to 3rd of November, in Frankfurt, Germany. At Booth#41G20, the first floor of Hall 4, Messe Frankfurt, SINOVAC will greet all visitors of CPHI and present its comprehensive portfolio. The Company will showcase the only inactivated COVID-19 vaccine approved for children as young as 6-months old, CoronaVac®; the quadrivalent influenza vaccine, QIV; the world-leading enterovirus type 71 vaccine, Inlive®; the varicella vaccine which provides 100% p

Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ:SVA), a leading provider of biopharmaceutical products in China, announced that the Chilean Public Health Institute (Instituto de Salud Pública, ISP) approved a phase II clinical trial for its inactivated Omicron strain COVID-19 vaccine and trivalent COVID-19 vaccine (ancestral, Delta and Omicron variants) on August 31st. The clinical trial will evaluate the immunogenicity and safety of one booster dose of the two candidate vaccines in adults who had received two booster doses of CoronaVac®, mRNA, or adenovirus vector COVID-19 vaccine. This study is the world's first study researching multivalent inactivated COVID-19 vaccine. In thi

Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, has filed its 2021 annual report on Form 20-F with the U.S. Securities and Exchange Commission for the year ended December 31, 2021. The Company also reported its unaudited financial for the second half and full year ended December 31, 2021. Second Half and Full Year 2021 Financial Summary Sales for the six months ended December 31, 2021 were $8.4 billion, compared to $442.9 million in the prior year period. Sales in 2021 were $19.4 billion, compared to $510.6 million in the prior year. The Company posted $3.4 billion of net income attributable to common sharehol

Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, announced today its unaudited financial results for the six months ended June 30, 2021. First Half of 2021 Financial Summary Sales for the six months ended June 30, 2021 were $11.0 billion, compared to $67.7 million in the prior year period. The Company posted $5.1 billion of net income attributable to common shareholders, or $51.42 per basic and $44.80 per diluted share, in the six months ended June 30, 2021, compared to net loss attributable to common shareholders of $12.6 million, or $0.13 loss per basic and diluted share, in the prior year period. Mr. Weidon

Sinovac Biotech Ltd. (NASDAQ:SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, has filed its 2020 annual report on Form 20-F with the U.S. Securities and Exchange Commission for the year ended December 31, 2020. The Company also reported its unaudited financial results for the fourth quarter ended December 31, 2020. Fourth Quarter and Full Year 2020 Financial Summary Sales for the fourth quarter of 2020 were $327.5 million, an increase from $81.1 million in the prior year period. Sales in 2020 were $510.6 million, an increase from $246.1 million in the prior year. Operating income for the fourth quarter increased by 583.7% from the prior

BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, announced today its unaudited financial results for the third quarter ended September 30, 2020. Third Quarter and Nine Months Ended 2020 Financial Summary Sales for the third quarter of 2020 were $115.5 million, an increase of 79.4% from $64.3 million in the prior year period. Sales for the nine months ended September 30, 2020, were $183.2 million, an increase of 11.1% from $164.9 million in the prior year period. Operating income for the third quarter of 2020 increased by 101.7% from the prior year period due to higher sales.

Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ:SVA), a leading provider of biopharmaceutical products in China, announced that the Company has completed the phase I clinical trial for its broad-spectrum neutralizing antibody product, the Anti-COVID-19 Antibody SA55 Injection ("SA55 Injection") in Beijing and has entered the phase II clinical trial in Shanghai after successfully enrolling its first participant recently. SINOVAC's SA55 Injection, which is intended for the treatment of COVID-19 infections, was approved for clinical trial in China on May 24, 2023. The phase I clinical trial has confirmed its preliminary safety profile in 40 healthy adults aged 18 to 65 in China. The

Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, announced today that its Board of Directors (the "Board of Directors") unanimously determined that the partial tender offer (the "Tender Offer") by Alternative Liquidity Index LP ("Alternative Liquidity") to acquire up to 10,000,000 common shares of Sinovac (the "Shares") for $0.03 per share in cash (the "Offer Price") is NOT advisable and is NOT in the best interests of the Company or its shareholders ("Shareholders"). Accordingly, the Board of Directors recommends that the Shareholders reject the Tender Offer and not tender their Shares for purchase pursuant to the Off

Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, confirmed today that it is aware of an unsolicited partial tender offer from Alternative Liquidity Index LP to purchase up to a maximum of 10,000,000 shares of the Company, representing approximately 10.05% of the Company's outstanding shares, for $0.03 per share in cash.

Upgrades For Algonquin Power & Utilities Corp (NYSE:AQN), Wells Fargo upgraded the previous rating of Equal-Weight to Overweight. In the third quarter, Algonquin Power showed an EPS of $0.11, compared to $0.15 from the year-ago quarter. The current stock performance of Algonquin Power shows a 52-week-high of $16.01 and a 52-week-low of $6.41. Moreover, at the end of the last trading period, the closing price was at $6.86. For FirstCash Holdings Inc (NASDAQ:FCFS), Stephens & Co. upgraded the previous rating of Equal-Weight to Overweight. FirstCash Hldgs earned $1.30 in the third quarter, compared to $0.84 in the year-ago quarter. The stock has a 52-week-high of $100.00 and a 52-week-low of

COVID-19 cases have spiked again in China, sparking fresh lockdown measures in the nation's capital. Jim Cramer has suggested that Chinese President Xi Jinping isn't telling the whole story.  "I don't know what's with President Xi other than the fact that it would be a terrible admission that their vaccines don't work," Cramer said Tuesday on CNBC's "Squawk On The Street." What To Know: COVID-19 cases have been rising in multiple districts throughout China. On Monday, Beijing officials urged residents of the Chaoyang district to stay at home, extending a request from the weekend. The Haizhu district in Guangzhou also extended its COVID-19 restrictions in some areas to Nov. 27, according to

Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ:SVA), a leading provider of biopharmaceutical products in China, today announced that it received prequalification from the World Health Organization (WHO) for its live attenuated varicella vaccine on November 3, 2022. This marks the first WHO prequalified Chinese varicella vaccine and the fourth SINOVAC vaccine to receive WHO approval. The varicella vaccine is derived from the Oka strain and propagated in SINOVAC's proprietary Human Diploid Cell (SV-1 strain), which is made by culturing and harvesting the virus, adding stabilizers and freeze-drying. According to a phase III efficacy study, the seroconversion rate of the vaccinated

Sinovac Biotech Ltd. (“SINOVAC” or the “Company”) (NASDAQ:SVA), a leading provider of biopharmaceutical products in China, announced that the Chilean Public Health Institute (Instituto de Salud Pública, ISP) approved a phase II clinical trial for its inactivated Omicron strain COVID-19 vaccine and trivalent COVID-19 vaccine (ancestral, Delta and Omicron variants) on August 31st. The clinical trial will evaluate the immunogenicity and safety of one booster dose of the two candidate vaccines in adults who had received two booster doses of CoronaVac®, mRNA, or adenovirus vector COVID-19 vaccine. This study is the world's first study researching multivalent inactivated COVID-19 vaccine. In this

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Alnylam Reports Upbeat Data From Amyloidosis Study Alnylam Pharmaceuticals Inc's (NASDAQ:ALNY) APOLLO-B Phase 3 study of patisiran for transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy met the primary endpoint of change from baseline in the 6-Minute Walk Test (6-MWT) at 12 months compared to placebo.  The study also met the first secondary endpoint of change from baseline in quality of life compared to placebo. Patisiran also demonstrated an encouraging safety and tolerability profile, with deaths numerically favoring the patisiran arm. The company plans to file a supplemental

Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ:SVA), a leading provider of biopharmaceutical products in China, announced that based on related clinical trials and studies of vaccination for local children and adolescents, the Health Bureau of the Government of the Hong Kong Special Administrative Region of the People's Republic of China has approved the Company's COVID-19 vaccine (CoronaVac), intended for children aged 6 months to 3 years. The vaccination schedule for this age group follows the same vaccination schedule of older children. Three doses of vaccines will be used for children aged six months to under three years of age, with the first two doses given 28 days apart fo